Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 12/20 | 0.46 |
| ▸ | GRK2 | P25098 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CALML3 | P27482 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL591482 | 0.91 | GRM2 (0.52) | GRM2 | |
| SCHEMBL590024 | 0.90 | F10 (0.56) | GRM2GRK2KMT2ACTDSP1SIGMAR1 | |
| SCHEMBL591678 | 0.90 | F10 (0.56) | GRM2GRK2KMT2ACTDSP1SIGMAR1 | |
| SCHEMBL590026 | 0.90 | F10 (0.56) | GRM2GRK2KMT2ACTDSP1SIGMAR1 | |
| SCHEMBL1712582 | 0.87 | GRK2 (0.49) | GRM2GRK2KMT2ACTDSP1SIGMAR1 | |
| SCHEMBL2294706 | 0.87 | GRK2 (0.49) | GRM2GRK2KMT2ACTDSP1SIGMAR1 | |
| SCHEMBL592102 | 0.85 | GRK2 (0.44) | GRM2GRK2KMT2ACTDSP1SIGMAR1 | |
| SCHEMBL591658 | 0.85 | GRM2 (0.49) | GRM2GRK2KMT2ACTDSP1SIGMAR1 | |
| SCHEMBL591159 | 0.84 | MAOA (0.59) | GRK2KMT2ACTDSP1SIGMAR1CALML3 | |
| SCHEMBL591161 | 0.84 | MAOA (0.59) | GRK2KMT2ACTDSP1SIGMAR1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114867-B2 | Oxazolidinone antibiotic derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20100137290-A1 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-03 | — | — | US | disclosed |
| EP-2146987-A2 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008126024-A2 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137290-A1 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | OXA1L, XDH, CCNY | GRM2 4516/4885GRK2 3830/4885KMT2A 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.